Eloralintide: four selected records, read side by side with their limits. This is a working editorial sample, not a systematic review or an independently reviewed clinical guideline.
Receptor assays and animal experiments, plus a randomized, blinded, placebo-controlled single-ascending-dose Phase 1 study in 48 healthy participants. Read the record.
Question
Does the engineered amylin analogue have a pharmacology and exposure profile that support further clinical investigation? Read the record.
Finding
The paper characterizes a 37-residue modified amylin analogue, reports preferential activity at human AMY1 receptors in its assays, and describes early human safety and pharmacokinetics. Read the record.
Limits
The small Phase 1 population and single-dose design do not establish long-term obesity efficacy; receptor selectivity differs across species, and animal comparisons are not clinical head-to-head results. Read the record.
Funding / conflicts
Lilly-led development research; consult the publication's author affiliations, funding and competing-interest disclosures. Read the record.
Record 2 · Peer-reviewed · Randomized Phase 2
48-week monotherapy trial in adults without type 2 diabetes
Double-blind, randomized, placebo-controlled trial at 46 US centers; 263 adults with obesity, or overweight plus a weight-related comorbidity, without type 2 diabetes. Read the record.
Primary endpoint
Percentage change in body weight from baseline at week 48. Read the record.
Finding
The efficacy-estimand mean change in the fixed 9 mg study arm was approximately −20% (95% CI −22.7 to −17.5; n=54), compared with −0.4% (−2.2 to 1.4; n=53) for placebo. Read the record.
Safety
Nausea and fatigue were common adverse events, with rates varying substantially between study groups; this summary is not a complete adverse-event table. Read the record.
Limits
The result is an arm-specific trial estimate, not a guaranteed individual outcome; it does not establish long-term safety, approval or superiority to retatrutide, which was not a comparator. Read the record.
Funding
Eli Lilly funded the trial; the primary paper identifies author affiliations and disclosures. Read the record.
Record 3 · Sponsor trial listing · Phase 3 protocol
ENLIGHTEN-1 is ongoing research, not a completed result
Phase III study of eloralintide in adults with obesity or overweight without type 2 diabetes, including a main phase and an extension phase. Read the record.
Status
The sponsor listing shows enrolling, an enrollment goal of 1,980 and trial dates January 2026 to July 2030, checked November 11, 2026. Read the record.
Finding
No completed efficacy result is presented on this trial listing; an enrollment goal is a target, not the number who have completed the study. Read the record.
Limits
A protocol or recruiting listing establishes that research is planned or underway; it is not proof of efficacy or regulatory approval, and trial status can change. Read the record.
Record 4 · Sponsor announcement · Phase 2b combination
EloraTZP is eloralintide plus tirzepatide, not monotherapy
Sponsor-reported 48-week, double-blind Phase 2b study with 367 randomized participants with obesity or overweight and type 2 diabetes, including monotherapy, combination and placebo groups. Read the record.
Finding
Lilly reported weight and A1C outcomes for combinations of eloralintide and tirzepatide; in this study the two compounds were administered as separate injections. Read the record.
Safety
The announcement reports gastrointestinal adverse events and discontinuation due to adverse events of 10.8%–27.0% across combination arms. Read the record.
Limits
This record is a sponsor announcement, not a substitute for full peer-reviewed reporting; its diabetes population and combination arms must not be merged with the 2025 monotherapy trial or described as eloralintide-versus-retatrutide evidence. Read the record.
How to read “−20%” responsibly
It is an estimated mean percentage change in a specified trial arm at a specified time, under that trial's efficacy estimand, not the percentage of people who benefited or a guaranteed personal result (primary paper).
Do not rank it against a number from a different trial without considering population, treatment, duration, estimand and missing data. The cited monotherapy trial did not compare eloralintide against retatrutide (trial design).
Pro is still planned, not open for purchase
This sample is free. The proposed $9/month membership, its final coverage and launch date have not been activated or guaranteed; existing public resources remain free.
